The story of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial release generated massive gains, the expiration of its exclusive rights opened the avenue to off-brand alternatives, dramatically reducing sales. This presents a particular risk for pharmaceutical companies relying on similar bl

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, producing billions in sales , its patent expiration created a wave of generic competition , significantly diminishing its position . While specific pharmaceutical companies may seek to capitalize on related treatments , t